0169-2800-15 · Liraglutide Injection · Novo Nordisk, Inc.
What is the status for 0169-2800-15 · Liraglutide Injection · Novo Nordisk, Inc.?
For 0169-2800-15, generic name is Liraglutide Injection; manufacturer is Novo Nordisk, Inc; status is Current; availability now is Limited Availability; fda note is Product will be available until discontinuation in January 2027, recorded from its source on 2026-11-04.
"initial_posting_date": "07/18/2023", "package_ndc": "0169-2800-15", "generic_name": "Liraglutide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide+Injection&st=d", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Product will be available until discontinuation in January 2027"
— api.fda.gov, retrieved 2026-11-04
- Package NDC
- 0169-2800-15 verified
- Generic name
- Liraglutide Injection verified
- Manufacturer
- Novo Nordisk, Inc. verified
- Status
- Current verified
- Availability now
- Limited Availability verified
- FDA note
- Product will be available until discontinuation in January 2027 verified
- Initial posting date
- 07/18/2023 verified
- Last update date
- 09/22/2026 verified
- Days in shortage
- 1205 our reading
- Reason for shortage
- Discontinuation of the manufacture of the drug verified
- Dosage form
- Injection verified
- Therapeutic category
- Endocrinology/Metabolism verified
Values marked our reading are our classification of what the source says — the source does not print them in those words. The quote below is the evidence for each one; judge it yourself.
Where each value comes from
The values above are stated away from the sentence quoted with the answer, so the passage that states them is shown here too.
Manufacturer, Status, Last update date, Reason for shortage, Dosage form and Therapeutic category
"update_date": "09/22/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current"
— all from api.fda.gov, retrieved 2026-11-04
Source
- api.fda.govhttps://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000